Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs

P. R. Cottrell, J. M. Streete, D. J. Berry, H. Schäfer, F. Pisani, E. Perucca, A. Richens

Research output: Contribution to journalArticlepeer-review

Abstract

The pharmacokinetics of phenylethylmalonamide (PEMA), a major metabolite of primidone, were investigated following administration of single oral doses (400 mg) to 6 normal subjects and 6 patients receiving chronic treatment with antiepileptic drugs. Peak serum PEMA levels were usually attained within 2-4 h after intake. The oral bioavailability estimated on the basis of the recovery of unchanged drug in the urine of normal subjects was at least 80%. Half-life values ranged from 17 to 25 h in normal subjects and from 10 to 23 h in the patients. No statistically significant difference in any of the calculated kinetic parameters could be found between the 2 groups. The data indicate that PEMA is readily absorbed from the gastrointestinal tract and that it is eliminated predominantly unchanged in the urine of man.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalEpilepsia
Volume23
Issue number3
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Pharmacokinetics of phenylethylmalonamide (PEMA) in normal subjects and in patients treated with antiepileptic drugs'. Together they form a unique fingerprint.

Cite this